CDSCO bans anti-cold drug combination for kids aged under four

Published On 2023-12-21 11:57 GMT   |   Update On 2023-12-21 11:57 GMT

To ensure the safety of infants and young children in the country, the Central Drugs Standard Control Organization (CDSCO) has recently banned the use of anti-cold fixed drug combination (FDC) of Chlorpheniramine Maleate IP 2mg and Phenylephrine HCL IP 5mg drop/ml in kids below 4 years of age.With this, Drugs Controller General of India (DCGI) Rajeev Raghuvanshi has asked the state and UT...

Login or Register to read the full article

To ensure the safety of infants and young children in the country, the Central Drugs Standard Control Organization (CDSCO) has recently banned the use of anti-cold fixed drug combination (FDC) of Chlorpheniramine Maleate IP 2mg and Phenylephrine HCL IP 5mg drop/ml in kids below 4 years of age.

With this, Drugs Controller General of India (DCGI) Rajeev Raghuvanshi has asked the state and UT drug controllers to direct all the manufacturers of the fixed-dose combination (FDC) of Chlorpheniramine Maleate IP 2mg and Phenylephrine HCL IP 5mg drop/ml under their jurisdiction to add warning that FDC should not be used in children below 4 years of age on label and package insert/ promotional literature of the drug.

For more details, check out the link given below:

CDSCO Bans Use Of Chlorpheniramine Maleate IP 2mg And Phenylephrine HCL IP 5mg Drop/Ml FDC In Kids Below 4 Years



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News